RG
Therapeutic Areas
Emergent BioSolutions Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BioThrax® (Anthrax Vaccine Adsorbed) | Prevention of anthrax disease | Approved |
| ACAM2000® | Prevention of smallpox disease | Approved |
| NARCAN® Nasal Spray | Emergency treatment of opioid overdose | Approved |
| Vaxchora® | Prevention of cholera | Approved |
| Anthrasil® | Treatment of inhalational anthrax | Approved |
| BAT® (Botulism Antitoxin) | Treatment of botulism poisoning | Approved |
| Trobigard® | Treatment of nerve agent poisoning | Approved |
| NuThrax™ (AV7909) | Prevention of anthrax disease | Phase 3 |
Leadership Team at Emergent BioSolutions
JC
Joseph C. Papa
Chairman of the Board & Interim Chief Executive Officer
RS
Richard S. Lindahl
Executive Vice President, Chief Financial Officer and Treasurer
SB
Sue Bailey, M.D.
Director
PW
Paul Williams
Senior Vice President, Products Business
KW
Kelly Warfield
Senior Vice President, Science & Development
AS
Atul Saran
Senior Vice President, Corporate Development & Strategy
ST
Sybil Tasker, M.D., MPH
Senior Vice President & Chief Medical Officer
EL
Eliot Lurier
Senior Vice President, Chief Accounting Officer (Interim)
AR
Adam R. Havey
Executive Vice President, Chief Operating Officer
JM
John M. Leonard, M.D.
Director